Great Novel Therapeutics Biotech & Medicals (ROCO:7427) LT-Debt-to-Total-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Great Novel Therapeutics Biotech & Medicals's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.01.

Great Novel Therapeutics Biotech & Medicals's long-term debt to total assets ratio declined from Jun. 2023 (0.02) to Jun. 2024 (0.01). It may suggest that Great Novel Therapeutics Biotech & Medicals is progressively becoming less dependent on debt to grow their business.

Great Novel Therapeutics Biotech & Medicals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals LT-Debt-to-Total-Asset Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial						-	-	0.02	0.02	0.01

Great Novel Therapeutics Biotech & Medicals LT-Debt-to-Total-Asset Calculation

Great Novel Therapeutics Biotech & Medicals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	10.881	/	644.849
	=	0.02

Great Novel Therapeutics Biotech & Medicals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	8.909	/	700.763
	=	0.01

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Great Novel Therapeutics Biotech & Medicals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals Headlines

No Headlines